semaglutide and ibs-d Patients with stable inflammatory bowel disease (IBD) comorbid obesity and/or diabetes who started GLP-1 receptor agonists (semaglutide or tirzepatide) alongside ongoing treatment did not have a lower risk for the relapse πReal-world data on GLP-1RA switching
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Oct 3 - Oct 8





/assets/images/provider/photos/2737000.jpeg)





















